US20040229852A1 - Pharmaceutical composition for enhancing immunity, and extract of Poria - Google Patents
Pharmaceutical composition for enhancing immunity, and extract of Poria Download PDFInfo
- Publication number
- US20040229852A1 US20040229852A1 US10/717,559 US71755903A US2004229852A1 US 20040229852 A1 US20040229852 A1 US 20040229852A1 US 71755903 A US71755903 A US 71755903A US 2004229852 A1 US2004229852 A1 US 2004229852A1
- Authority
- US
- United States
- Prior art keywords
- pcm
- individual
- extract
- poria extract
- poria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000284 extract Substances 0.000 title claims abstract description 62
- 230000036039 immunity Effects 0.000 title claims abstract description 32
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
- 241001619461 Poria <basidiomycete fungus> Species 0.000 title claims description 42
- 230000002708 enhancing effect Effects 0.000 title claims description 20
- 238000000034 method Methods 0.000 claims abstract description 38
- ZQIOPEXWVBIZAV-ZKYCIREVSA-N lanostane Chemical class CC([C@@H]1CC2)(C)CCC[C@]1(C)[C@@H]1[C@@H]2[C@]2(C)CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 ZQIOPEXWVBIZAV-ZKYCIREVSA-N 0.000 claims abstract description 31
- 241000282461 Canis lupus Species 0.000 claims abstract description 20
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 20
- 241001619444 Wolfiporia cocos Species 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 241000282414 Homo sapiens Species 0.000 claims abstract description 4
- 241001558929 Sclerotium <basidiomycota> Species 0.000 claims abstract description 3
- 238000000855 fermentation Methods 0.000 claims abstract description 3
- 230000004151 fermentation Effects 0.000 claims abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 81
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000012046 mixed solvent Substances 0.000 claims description 10
- 239000000741 silica gel Substances 0.000 claims description 10
- 229910002027 silica gel Inorganic materials 0.000 claims description 10
- 239000003480 eluent Substances 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 238000004809 thin layer chromatography Methods 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 4
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- 239000011630 iodine Substances 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000002207 metabolite Substances 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 11
- 230000003389 potentiating effect Effects 0.000 abstract description 10
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 210000004027 cell Anatomy 0.000 description 59
- 210000004989 spleen cell Anatomy 0.000 description 51
- 241000699670 Mus sp. Species 0.000 description 31
- 230000000694 effects Effects 0.000 description 28
- 230000028327 secretion Effects 0.000 description 26
- 238000003556 assay Methods 0.000 description 20
- 210000000952 spleen Anatomy 0.000 description 17
- 102000004127 Cytokines Human genes 0.000 description 15
- 108090000695 Cytokines Proteins 0.000 description 15
- 102000003814 Interleukin-10 Human genes 0.000 description 14
- 108090000174 Interleukin-10 Proteins 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 210000001744 T-lymphocyte Anatomy 0.000 description 14
- 238000011534 incubation Methods 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 230000010261 cell growth Effects 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 11
- 108010074328 Interferon-gamma Proteins 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 102100037850 Interferon gamma Human genes 0.000 description 9
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 9
- 210000003719 b-lymphocyte Anatomy 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 239000000287 crude extract Substances 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 210000000822 natural killer cell Anatomy 0.000 description 6
- 230000000242 pagocytic effect Effects 0.000 description 6
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 5
- 241000283707 Capra Species 0.000 description 5
- 108010062580 Concanavalin A Proteins 0.000 description 5
- 206010057249 Phagocytosis Diseases 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 230000001464 adherent effect Effects 0.000 description 5
- 230000003190 augmentative effect Effects 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000008782 phagocytosis Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000003393 splenic effect Effects 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 229930182816 L-glutamine Natural products 0.000 description 4
- 231100000002 MTT assay Toxicity 0.000 description 4
- 238000000134 MTT assay Methods 0.000 description 4
- URQXTERJYHNRFO-ZMXSVVRFSA-N [H][C@@]12CC=C3C(=CC[C@]4(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(=O)O)[C@H](O)C[C@@]34C)[C@@]1(C)CCC(=O)C2(C)C.[H][C@@]12CC=C3C(=CC[C@]4(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(=O)O)[C@H](O)C[C@@]34C)[C@@]1(C)CCC(O)C2(C)C.[H][C@@]12Ccc3c(cC[C@]4(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(=O)O)[C@H](O)C[C@@]34C)[C@@]1(C)CCC(O)C2(C)C.[H][C@@]12Ccc3c(cC[C@]4(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(=O)O)[C@H](O)C[C@@]34C)[C@@]1(C)CCC(OC(C)=O)C2(C)C Chemical compound [H][C@@]12CC=C3C(=CC[C@]4(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(=O)O)[C@H](O)C[C@@]34C)[C@@]1(C)CCC(=O)C2(C)C.[H][C@@]12CC=C3C(=CC[C@]4(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(=O)O)[C@H](O)C[C@@]34C)[C@@]1(C)CCC(O)C2(C)C.[H][C@@]12Ccc3c(cC[C@]4(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(=O)O)[C@H](O)C[C@@]34C)[C@@]1(C)CCC(O)C2(C)C.[H][C@@]12Ccc3c(cC[C@]4(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(=O)O)[C@H](O)C[C@@]34C)[C@@]1(C)CCC(OC(C)=O)C2(C)C URQXTERJYHNRFO-ZMXSVVRFSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- -1 triterpene compounds Chemical class 0.000 description 4
- 241000699800 Cricetinae Species 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000003024 peritoneal macrophage Anatomy 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 2
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000000743 Interleukin-5 Human genes 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 101100520094 Methanosarcina acetivorans (strain ATCC 35395 / DSM 2834 / JCM 12185 / C2A) pcm2 gene Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 102100033422 Pericentriolar material 1 protein Human genes 0.000 description 2
- 101710095344 Pericentriolar material 1 protein Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 229940100602 interleukin-5 Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- FTZIQBGFCYJWKA-UHFFFAOYSA-N 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 FTZIQBGFCYJWKA-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- QYFKNMSHSIGYDB-MNEYWARDSA-N C=C(CC[C@@H](C(=O)O)[C@H]1[C@H](O)C[C@@]2(C)C34CC[C@@]5(OO3)C(C)(C)[C@@H](O)CC[C@]5(C)C4=CC[C@]12C)C(C)C.[H][C@@]12CC=C3C(=CC[C@]4(C)[C@@H]([C@@H](CCC=C(C)C)C(=O)O)CC[C@@]34C)[C@@]1(C)CC[C@H](O)C2(C)C.[KH].[K][K].[K][K] Chemical compound C=C(CC[C@@H](C(=O)O)[C@H]1[C@H](O)C[C@@]2(C)C34CC[C@@]5(OO3)C(C)(C)[C@@H](O)CC[C@]5(C)C4=CC[C@]12C)C(C)C.[H][C@@]12CC=C3C(=CC[C@]4(C)[C@@H]([C@@H](CCC=C(C)C)C(=O)O)CC[C@@]34C)[C@@]1(C)CC[C@H](O)C2(C)C.[KH].[K][K].[K][K] QYFKNMSHSIGYDB-MNEYWARDSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 1
- 101001033265 Mus musculus Interleukin-10 Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 0 [2*]C1CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(=O)O)[C@H](O)C[C@@]4(C)C3=CC[C@@]2([H])C1(C)C.[2*]C1CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(=O)O)[C@H](O)C[C@@]4(C)C3=C[C@H]([5*])[C@@]2([H])C1(C)C.[2*][C@H]1CC[C@]2(C)C3=C(CC[C@@]2([H])C1(C)C)[C@]1(C)C[C@@H](O)[C@H]([C@@H](CCC(=C)C(C)C)C(=O)O)[C@@]1(C)CC3.[5*][C@H]1C=C2C(=CC[C@]3(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(=O)O)[C@H](O)C[C@@]23C)[C@@]2(C)CCC(=O)[C@@]([6*])(C)[C@]12[H] Chemical compound [2*]C1CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(=O)O)[C@H](O)C[C@@]4(C)C3=CC[C@@]2([H])C1(C)C.[2*]C1CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(=O)O)[C@H](O)C[C@@]4(C)C3=C[C@H]([5*])[C@@]2([H])C1(C)C.[2*][C@H]1CC[C@]2(C)C3=C(CC[C@@]2([H])C1(C)C)[C@]1(C)C[C@@H](O)[C@H]([C@@H](CCC(=C)C(C)C)C(=O)O)[C@@]1(C)CC3.[5*][C@H]1C=C2C(=CC[C@]3(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(=O)O)[C@H](O)C[C@@]23C)[C@@]2(C)CCC(=O)[C@@]([6*])(C)[C@]12[H] 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- GPWDPLKISXZVIE-UHFFFAOYSA-N cyclo[18]carbon Chemical compound C1#CC#CC#CC#CC#CC#CC#CC#CC#C1 GPWDPLKISXZVIE-UHFFFAOYSA-N 0.000 description 1
- 238000007822 cytometric assay Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- YVHPHQBRUPLYOS-UHFFFAOYSA-N dichloromethane;methane Chemical compound C.ClCCl YVHPHQBRUPLYOS-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108010009004 proteose-peptone Proteins 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 210000000463 red nucleus Anatomy 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Definitions
- the present invention relates to a pharmaceutical composition containing lanostane as a potent component thereof for enhancing immunity.
- the present invention further relates to an extract of Poria cocos (Schw) Wolf for the purpose of immunity enhancement.
- the Poria extract has tonic effect, as well as a smoothing effect on stomach disorder.
- the Poria extract is classified as a tranquilizer and a uretic agent.
- the Poria extract is used as one of essential ingredients of the Chinese medicine prescription for vital activity.
- the Poria extract has a favorable effect on tumor prevention, and that the Poria extract is beneficial to immunity enhancement and gastrointestinal system of a person suffering from a chronic disease.
- Japan Patent Publication Numbers 55-111791 and 57-38794 disclose an extract which is obtained from the cultivated mycelia of Poria cocos (Schw) Wolf and is effective in tumor prevention.
- the Japan Patent Publication No. 55-111422 discloses an extract which is directly obtained from Poria cocos (Schw) Wolf for use in tumor prevention.
- the Japan Patent Publication No. 8-119864 discloses an extract which is obtained by extracting Poria cocos (Schw) Wolf with methanol. By separation, triterpene compounds such as lanostanes and horranes are obtained from the extract and are used as anti-emetic agents.
- 9-025232 discloses triterpene compounds, which is obtained by extracting Poria cocos (Schw) Wolf with methanol. The compounds are useful as a tumor promotion-inhibiting agent.
- the Japan Patent Publication No. 9-176184 discloses an extract of Poria cocos (Schw) Wolf, which is then refined to produce triterpene compounds for use as an agent for inhibiting inflammation and tumor promotion.
- the China Patent Publication No. 1008183 discloses a method of making a Poria extract containing triterpene compounds.
- the method involves extracting the Poria powder with an acidic alcohol, neutralizing the extract with a basic solution, concentrating the neutralized solution, adjusting the pH thereof to about 10 and filtering the solution, acidifying the filtrate to form a precipitate, washing the precipitate after filtration, and drying the washed precipitate.
- the Poria extract so obtained is found to have a tumor-preventive effect and an immunity activation effect.
- the primary objective of the present invention is to provide a method of prepare a potent component having an improved biological activity from Poria cocos (Schw) Wolf, and a Poria extract containing the potent component.
- a pharmaceutical composition for enhancing immunity of mammal contains one or more lanostane compounds.
- the pharmaceutical composition is used to adjust or enhance immunity and can be dispensed by a dermal, oral, or hypodermic administration, and may be in a slow-release dosage form.
- the present invention makes use of the immunity experiments to verify the pharmacological properties of the potent component of the Poria extract.
- the potent component is a low polarity portion (PCM), which contains major compounds of K1, K2, K3, K4, and trace of K4a, K4b, K5, K6a, K6b, which are all lanostane compounds.
- PCM low polarity portion
- the compounds of K1, K2, K3, and K4 have an immunity enhancement effect.
- the method of the present invention makes use of the conventional extraction process, by means of which a crude extract is obtained.
- a chromatographic separation is used to separate constituents of the crude extract, which include a lanostane fraction and a horranostane fraction.
- the lanostane fraction is relatively smaller in polarity than the NYCanostane fraction.
- the position of the lanostane fraction is identified by the thin layer chromatography, which has a chromatographic value (Rf) being.
- PCM Poria cocos
- 2.6 grams of PCM are obtained from one kilogram of Poria cocos (Schw) Wolf.
- three grams of a crude extract are obtained from one kilogram of Poria cocos (Schw) Wolf.
- this crude extract is purified by the method of the present invention, only one gram of PCM is obtained.
- FIG. 1 shows a flow diagram of a method of the present invention for making lanostane compounds from Poria cocos (Schw) Wolf.
- FIG. 2 shows a flow diagram of making a Poria extract in accordance with a method disclosed by the China Patent Publication No. 1008183, and a low polarity portion of the Poria extract according to the present invention.
- the lanostane fraction has no toxic effect on vat spleen cells and is pharmacologically effective.
- the NYCanostane fraction has a toxic effect on rat spleen cells.
- the present invention discloses a pharmaceutical composition capable of enhancing immunity of mammal, such as Homo sapiens .
- the composition contains a therapeutically effective amount of lanostane having the following chemical formula (I) as an active ingredient, and a pharmaceutically acceptable carrier or diluent for the active ingredient:
- R 1 is either H or CH 3 ;
- R 2 is OCOCH 3 , C ⁇ O or OH;
- R 3 is H or OH;
- R 4 is —C( ⁇ CH 2 )—C(CH 3 ) 2 R a , wherein R a is H or OH, or —CH ⁇ C(CH 3 )—R b , wherein R b is CH 3 or CH 2 OH; R 5 is H or OH; and R 6 is CH 3 or CH 2 OH.
- the pharmaceutical composition comprises 0.1-60% of the lanostane (I) by weight of the composition and is orally administered.
- the present invention also discloses a Poria extract capable of enhancing immunity of mammal.
- the extract contains 5-60%, preferably 10-20%, of the lanostane (I) by weight of the extract.
- the extract is substantially devoid of NYCanostane.
- the present invention covers a method for the preparation of the Poria extract.
- the method includes a first step in which the metabolites, the fermentation products, and the sclerotium of Poria cocos (Schw) Wolf are extract by a solvent, such as water, methanol, ethanol, or a mixture thereof, thereby resulting in production of a liquid extract, which is then concentrated to form a concentrated substance.
- the concentrated substance is introduced into a silica gel column, and is eluted with an eluent having a low polarity. As a result, an eluate is produced and collected.
- the concentrated substance is further extracted with a two-phase solvent containing methanol and n-hexane in a volumetric ratio of 1:1.
- the methanol layer is separated and is concentrated to form a concentrate, which is used as a feed to the silica gel column.
- the low polarity eluent is a mixed solvent containing dichloromethane and methanol in a volumetric ratio of 96.5:3.5.
- the lanostane (I) has the following structures:
- the present invention also discloses a method of enhancing immunity of an individual comprising administering to the individual a therapeutically effective amount of the lanostane (I) of the present invention.
- the present invention also discloses a method of enhancing immunity of an individual comprising administering to the individual a therapeutically effective amount of the Poria extract of the present invention.
- a Poria powder was made of 30 kilograms of the China-grown Poria cocos (Schw) Wolf.
- the Poria powder was extracted with 120 L 95% alcohol for 24 hours.
- the mixture was filtered to obtain a filtrate.
- the residue was extracted and filtered for another three cycles.
- the filtrates were combined and concentrated to bring about a dried extract in amount of 265.2 grams.
- a separation of the dry solid was carried out by means of a silica gel column, which was filled with silica gel 10-40 times of the weight of the dry solid.
- the silica gel having a diameter of 70-230 mesh was made by Merck corporation with a code of Silica Gel 60.
- TLC thin layer chromatography
- the K1 fraction (3.5 g) was further subjected to a high performance liquid chromatography (HPLC) using a carbon-18 column and a mobile phase of methanol-water (90:10)). 3.0 grams of K1 component was obtained.
- HPLC high performance liquid chromatography
- the PCM-1 fraction was separated into K3, K5, and trace K1 components.
- the K3 component was further purified to yield K3 (1.93 g) by means of the same HPLC and a mobile phase of methanol-water (84:16).
- the K5 component was further purified with the same HPLC and two mobile phases of methanol-water (93:7) and (91:9) in sequence to yield K5 (47.6 mg).
- K6a 21.4 mg
- K6b 90.7 mg
- the K4 trace component was subjected to the same HPLC and a mobile phase of methanol-water (76:24) to yield K4a (66.0 mg) and K4b (86.8 mg).
- K1 mixture
- EI-MS major component, 528[M] + ; trace component, 526[M] +
- K1 (major component): 13 C-NMR ( ⁇ c): 35.4 (c-1), 24.5 (c-2), 80.6 (c-3), 38.0 (c-4), 50.7 (c-5), 18.4 (c-6), 26.8 (c-7), 135.0 (c-8), 134.4 (c-9), 37.2 (c-10), 20.9 (c-11), 29.7 (c-12), 48.8 (c-13), 46.3 (c-14), 43.6 (c-15), 26.6 (c-16), 57.3 (c-17), 17.8 (c-18), 19.2 (c-19), 48.6 (c-20), 178.6 (c-21), 31.6 (c-22), 33.2 (c-23), 156.1 (c-24), 34.1 (c-25), 22.0 (c-26), 21.9 (c-27), 28.0 (c-28), 16.8 (c-29), 25.4 (c-30), 107.0 (c-31), 21.1 ( C H 3 COO—), 170.5 (CH 3 C OO—)
- K2 mixture
- EI-MS major component
- 486[M] + trace component
- K2 (major component): 13 C-NMR ( ⁇ c): 36.6 (c-1), 29.1 (c-2), 78.5 (c-3), 40.0 (c-4), 51.4 (c-5), 19.2 (c-6), 27.4 (c-7), 135.4 (c-8), 135.3 (c-9), 37.9 (c-10), 21.4 (c-11), 30.2 (c-12), 49.3 (c-13), 46.7 (c-14), 44.2 (c-15), 77.1 (c-16), 57.8 (c-17), 18.2 (c-18), 19.8 (c-19), 49.2 (c-20), 179.4 (c-21), 32.1 (c-22), 33.7 (c-23), 156.5 (c-24), 34.6 (c-25), 22.5 (c-26), 22.4 (c-27), 29.1 (c-28), 16.8 (c-29), 25.9 (c-30), 107.5 (c-31)
- K3 mp: 278-280° C.
- K4 mp: >300° C.
- K4a mp: 284-287° C.
- K4b mp: 230-232° C.
- K5 mp: 274-275° C.
- K6a mp: 248-250° C.
- K6b mp: 267-270° C.
- a powder was made of two kilograms of the China-grown Poria cocos (Schw) Wolf.
- a crude extract in an amount of 6.0 g was obtained, as shown in FIG. 2.
- the PCM-E and the PCW-E prepared in Example 2 were orally administered to animals in a dose of 40 mg/kg per day for the purpose of testing the effect of these two portions on growth of spleen cells (immunity cells) of the animals.
- the immune system of the animals will be enhanced, if the growth of spleen cells thereof are stimulated; and will be adversely affected, if the growth of spleen cells are inhibited, i.e. the spleen cells are killed due to toxicity.
- the spleen cells were cultivated in vitro for five days before they were compared for cellular growth by means of MTT assay, which was determined by an immunological research method described hereinafter. The results are listed in the Table 1.
- the cellular growth of the spleen of the mice was apparently promoted on the third day and the fourth day in the wake of oral administration of PCM-E. Based on the statistic view point, there is no difference in terms of cellular growth among the control group and the experimental group. However, the number of the alive spleen cells of the mice was apparently lower than that of the control group on the third day and the fourth day in the wake of oral administration of PCW-E. In another words, the cellular growth of the spleen of the experimental group is apparently weakened as compared to the control group. This means that PCW-E is cytotoxic.
- the lanostane-containing low polarity portion has no inhibitive effect on cellular growth of the spleen.
- the PCM portion has a promotive effect on cellular growth of the spleen.
- the horranostane-containing high polarity portion (Rf ⁇ 0.1) has an inhibitive effect on cellular growth of the spleen.
- the Poria extract of the present invention is devoid of the horranostane fraction (PCW-E). On the contrary, the Poria extract obtained by the prior art methods contains the PCW-E capable of inhibiting cellular growth of the spleen.
- the potent component of the Poria cocos (Schw) Wolf is a lanostane-containing low polarity portion, which is capable of enhancing immunity of human body.
- a silica gel thin layer chromatography and a silica gel column chromatography can be employed to separate the promotive components from the inhibitive components of Poria cocos (Schw) Wolf.
- the Poria extract obtained by the method of the present invention is devoid of the inhibitive components, which are explainedanostanes and high polar molecules contained in the high polarity portion, PCW-E. For this reason, the method of the present invention is superior to the prior art methods.
- the animal experiments of the present invention are carried out by an oral administration of PCM-E and PCW-E to animals.
- the administrations of PCM-E and PCW-E of the present invention take place in vivo other than in vitro. Because in vitro study of pharmaceutical compound on spleen cells dose not reflect actual effects of the pharmaceutical compound on cellular growth of the animal spleen in light of absence of interactions between cellular metabolism and the pharmaceutical compound. It is therefore readily apparent that the present invention is reliable and meaningful.
- Poria extract and the purified compounds from the Poria extract by chromatography prepared according to the methods of the present invention were tested by various immunity response experiments listed in the following.
- the PCM fraction of Poria extract and the lanostane compounds K1, K2, K3 and K4 purified therefrom in Example 1 exhibit immunity enhancement activities in immune cells (T cells/B cells) in the following immunity response tests, and, as shown in Table 2 to Table 10, K1, K2, K3 and K4 compounds are potent at dosage low than 2.5 or 5.0 mg/kg.
- mice Female mice, 6-8 weeks old, were used throughout the experiment.
- the animals were purchased from National Laboratory Animal Center, Taipei, Taiwan.
- the mice were housed in the Individual Ventilation Cage System, which provided an environment of Specific Pyrogen-Free.
- the facilities had 12-h day/night rhythm, 24-26° C. and 30-70% humidity in air.
- Mice were fed autoclaved water and rodent chow, and the bedding was sterilized by autoclave also.
- the feedstock purchased from animal center of National Taiwan University composed of crude proteins (>23.0%), crude fat (>4.5%), crude fiber ( ⁇ 6.0%), ash ( ⁇ 8.0%), added minerals ( ⁇ 3.0%) and water ( ⁇ 12%). After transport, the mice were allowed to rest for two weeks before the experiments were started.
- the animals were divided into four groups and oral administration with 1 ml of PCM, ranging from 10, 40 to 80 mg/kg/day, for four days.
- the dosage of oral administration had a range from 2.5, 5, 10 to 20 mg/kg/day, which were a quarter of the dosage used for PCM study.
- the control group was the mice feeding with an equal volume of saline (0.85% of NaCl). Mice were sacrificed at day five, and both the serum and spleen cells were collected. The sera were subsequently used to measure the concentration of IgG, IgM and IgA.
- the spleen cells were plated onto a 100 mm diameter culture plate and incubated at 37° C. for three hours.
- the non-adherent cells containing T-lymphocytes, B-lymphocytes and NK cells were collected and properly diluted as described in each assay.
- the mouse to be sacrificed was cervical dislocated and sterilized with 70% ethanol.
- the cardiac punctuation was performed first to withdraw the blood. After the haemagglutination, the blood sample was subjected to centrifugation and the serum was collect.
- the peritoneum was opened to remove the spleen.
- the fresh spleen was transferred to a culture plate containing 10 ml of RPMI-1640 culture medium.
- the spleen was then ground over a fine mesh to release the spleen cells.
- the spleen cells suspending in the medium were then removed and transferred to a 50-ml conical centrifuge tube. The tube was subjected to centrifugation at 1300 rpm for 10 min.
- the supernatant was discarded and the pellet was re-suspended in 1 ml of cold RBC lysing buffer containing EDTA-NH 4 Cl.
- the cells were incubated at room temperature for 10 min, followed by washing the cells three times with culture medium by centrifugation.
- the spleen cells were plated onto a 100 mm diameter culture plate and incubated at 37° C. for three hours.
- the non-adherent cells containing T-lymphocytes, B-lymphocytes and NK cells were collected and properly diluted as described in each assay.
- MTT assay is the method routinely used for estimating the viable cell number and viability of the cultured cells.
- the basic principle is that the only mitochondria in a viable cells contain biologically activated oxido-reductive enzymes. The enzymes interact with MTT reagents to convert the chemical into a relatively insoluble blue crystal. The crystal is then solublized in an acidic isopropanol and the absorbence at 570 nm in each well was read using an ELISA reader (EL311, BioTek, VT).
- the spleen cells suspended in a medium containing RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, antibiotics and 1 ⁇ g/ml concanavalin A (Con A) were cultured in the 96-well flat-bottom plate (5 ⁇ 10 5 cells/100 ⁇ l/well) for 5 days. MTT assay was performed at day 3, 4 and 5. MTT tetrazolium (3-(4-5-dimethylthiazol-2-yl)-2,5-diphenyltertrazolium bromide) (5 mg/ml in phosphate-buffered saline) (Sigma Chemical, St.
- Leuis, Mo. was added to the spleen cells (20 ⁇ l MTT per 100 ⁇ l cells), and plates were incubated at 37° C. for 4 h. Acid-isopropanol (100 ⁇ l of 0.04 N HCL in isopropanol) was added to all wells and mixed completely to dissolve the dark blue crystals. After 20 minutes at room temperature to ensure that all crystals were dissolved, the plates were read on an EIA reader at 570 nm.
- ELISA was performed in our study to measure the immunoglobulin concentration. Briefly, the spleen cells (5 ⁇ 10 5 cells/ml) were cultured in a medium containing RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, antibiotics and 5 ⁇ g/ml lipopolysaccharide (LPS; 1 ⁇ g/10 5 cells) for 5 days. LPS is a polyclonal activator of B lymphocyte. Culture spleen cell supernatants were collected at day 3, 4 and. 5. IgA, IgG and IgM concentrations were measured using a sandwich ELISA technique.
- FBS fetal bovine serum
- LPS lipopolysaccharide
- a 96-well microtiter plate (Nunc-Immuno Plate, MaxiSorp, Nunc, Denmark) was precoated with 100 ng/well of capture antibodies at 4° C. overnight.
- the capture antibody was a rabbit anti-mouse IgG+IgA+IgM antibody (Zymed Laboratory, CA).
- the plate was washed with PBS-0.05% Tween 20 solution and blocked with PBS-1% gelatin. After the blocking, the properly diluted samples (1/10 5 diluted) and standard IgG ranged from 0.25 ⁇ g/ml to 0.039 ⁇ g/ml were added (100 ⁇ l/well). The plate was then incubated at 37° C. for 2 h.
- HRP-conjugated goat anti-mouse IgG (1:2,000 diluted; anti-whole IgG molecule; Zymed Laboratory, CA) was added (100 ⁇ l/well). After 1 h of incubation at 37° C., the color was developed using a substrate solution containing 0.1 M citrate buffer, pH 4.5, 0.03% H 2 O 2 and 0.1% of o-phenylenediamine. The absorbence at 490 nm in each well was read using an ELISA reader (EL311, BioTek, VT), and the data was analyzed using log-logit model.
- IgM assay was similar to that for IgG assay, except that the samples were 1/10 4 diluted and standard IgM ranged from 1 ⁇ g/ml to 0.0156 ⁇ g/ml were added (100 ⁇ l/well).
- the secondary antibody for the assay was HRP-conjugated goat anti-mouse IgM (1:1,000 diluted; heavy chain-specific; Zymed Laboratory, CA).
- IgA assay was similar to that for IgG assay, except that the samples were 1/10 4 diluted and standard IgA ranged from 1 ⁇ g/ml to 0.0156 ⁇ g/ml were added (100 ⁇ l/well).
- the secondary antibody for the assay was HRP-conjugated goat anti-mouse IgA (1:1000 diluted; Zymed Laboratory, CA).
- the spleen cells (1 ⁇ 10 6 cells/ml) were cultured in a medium containing RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, antibiotics and 1 ⁇ g/ml concanavalin A (Con A) for 3 days.
- Con A is one of the polyclonal activators for T lymphocyte.
- Culture spleen cell supernatants were collected.
- the IFN ⁇ and IL-10 concentrations were measured using a cytokine ELISA set (Cyto Set ELISA kit) purchased from R&D Systems (MN, USA).
- Cyto Set ELISA was performed as follows: A 96-well microtiter plate (Nunc-Immuno Plate, MaxiSorp, Nunc, Denmark) was precoated with capture antibodies at 4° C. overnight. The capture antibody was a rat monoclonal antibody to mouse IL-10. The samples to be tested and standard IL-10 ranged from 500 pg/ml to 15.6 pg/ml were added (100 ⁇ l/well). The plate was then incubated at 37° C. for 20 min. At the end of incubation, the plate was washed five times, followed by adding the biotinylated goat anti IL-10 polyclonal antibody.
- the color was developed by incubating the plate with a HRP-conjugated streptoavidin (Zymed, CA, USA), followed by a substrate solution containing hydrogen peroxide and tetramethylbenezidine (TMB). The reaction continued for 30 min at room temperature, and was stopped by adding 100 ⁇ l of 2N of sulfuric acid. The absorbence at 450 nm in each well was read using an ELISA reader (EL311, BioTek, Winooski, Vt.), and the data was analyzed using log-logit model.
- HRP-conjugated streptoavidin Zymed, CA, USA
- TMB tetramethylbenezidine
- Cyto Set ELISA of IFN- ⁇ was similar to that of IL-10, except that the capture antibody was a rat monoclonal antibody to mouse IFN- ⁇ , and secondary antibody was biotinylated goat anti IFN- ⁇ polyclonal antibody.
- CD3 pan-T marker
- CD4 helper T cell maker
- CD8 Cytotoxic T cell marker
- CD3, CD4 and CD8 expressions were monitored using a CY-Chrome conjugated hamster anti-mouse CD3 antibody (Becton Dickinson, San Jose, Calif.), PE-conjugated hamster anti-mouse CD4 antibody (Becton Dikinson, San Jose, Calif.) and FITC-conjugated hamster anti-mouse CD8 antibody (Becton Dikinson, San Jose, Calif.), respectively.
- CY-Chrome conjugated hamster anti-mouse CD3 antibody Becton Dickinson, San Jose, Calif.
- PE-conjugated hamster anti-mouse CD4 antibody Becton Dikinson, San Jose, Calif.
- FITC-conjugated hamster anti-mouse CD8 antibody Becton Dikinson, San Jose, Calif.
- the non-adherent spleen cells were washed three times with sterile cold PBS, followed by adjusting the cells to 1 ⁇ 10 6 cells/ml. Each 1 ⁇ 10 6 cells were mixed with 1 ⁇ l of indicated fluorescence-conjugated antibody and incubated at room temperature in the dark for 15 min. After the incubation, the cells were washed with cold PBS and were pelleted by contrifugation at 200 ⁇ g for 10 min. The pellet was dispersed and mixed with 500 ⁇ l of 1.0% of paraformaldehyde. The percentage of CD3 + cells in splenic lymphocytes and the percentage of CD4 + 8 ⁇ and CD4 ⁇ 8 + cells in CD3 + cell population were analyzed in flow cytometry.
- a LIVE/DEAD cell-mediated cytotoxicity kit (Molecular Probes, Eugene, Oreg.) was used for the assay. This two-color fluorescence assay allows direct assessment of cell-mediated cytotoxicity and yields cytotoxicity measurements that correlate well with 51 Cr release assay.
- the target cell using in our assay system was YAC-1 cells (ATCC, TIB-160). Briefly, the exponentially growth YAC-1 cells were harvested and washed with complete culture medium (RPMI 1640 supplemented with 10% fetal bovine serum, 2 mM L-glutamine and antibiotics).
- the cells were adjusted to 1 ⁇ 10 6 cells/ml and 20 ⁇ l of DiOC 18 (3,3′-diocatadecyloxacarbocyanine) were added for each ml of target cells. The cells were incubated at 37° C. for 20 min. The DiOC 18 reagent created a green fluorescence membrane stain on the target cells. The cells were then washed twice with PBS and suspended in complete culture medium at a concentration of 2 ⁇ 10 5 cells/ml. Non-adherent spleen cells (effector cells) were washed with Hank's balance salt solution for three times and suspended in complete culture medium at a concentration of 1 ⁇ 10 7 cells/ml.
- DiOC 18 3,3′-diocatadecyloxacarbocyanine
- the effector cells were then two-fold diluted to 5 ⁇ 10 6 cells/ml and 2.5 ⁇ 10 6 cells/ml.
- the equal volume (e.g. 200 ⁇ l) of effector cells and target cells was mixed to make the final Effector:Target ratio (E:T ratio) to 50:1, 25:1 and 12.5:1, respectively.
- the cell mixture was incubated at 37° C. for two hours, followed by adding 50 ⁇ l of propidium iodide.
- the propidium iodide can penetrate into the cells with damaged plasma membranes and stain the nuclear with red fluorescence.
- the cells were pelleted by centrifugation at 1000 ⁇ g for 30 seconds and incubated at room temperature for another 10 min.
- the tube was tapped gently to dislodge the pellets and then vortexed to re-suspend completely.
- the samples were ready for analyzing in the flow cytometry.
- the dead target cells had coincident green-membrane and red-nuclear staining.
- the live target cells were green on the membrane.
- the dead effector cells had only red-nucleus staining.
- mice were divided into four groups and oral administration with 1 ml of PCM-K1, ranging from 2.5 mg/kg/day to 20 mg/kg/day for four consecutive days.
- the control group was composed of mice injected with an equal volume of saline (0.85% of NaCl). The animals were i.p. injected with 2.5 ml of 10% proteose peptone at day two and sacrificed by cervical dislocation at day five.
- the peritoneal cavity was injected with 2 ml of the divalent cation-free, serum-free DMEM. The cavity was then gently massaged for 30 second, and the peritoneal fluid together with medium and peritoneal exudate cells were withdrew using a 25 G syringe. The cells were washed with complete DMEM culture medium and adjusted to 1 ⁇ 10 7 cells/ml. The cells were incubated on ice for 10 min, followed by mixing 1 ⁇ 10 6 cells with 5 ⁇ 1 06 fluorescent labeled particles. The particles for phagocytosis assay were fluorescein-laeled Escherichia coli (K-12 strain) BioParticles (Molecular Probes, Eugene, Oreg.).
- the cells were divided into experimental group and control group.
- the experimental group was incubated for 15 min at 37° C., followed by adding 100 ⁇ 11 of ice cold Quenching solution (1.25 mg/ml trypan blue).
- the control group was incubated at 0° C., instead.
- the cells from both groups were washed twice with PBS and pelleted by centrifugation at 150 ⁇ g for 5 min.
- the contaminated erythrocytes were removed by adding ACK lysing solution.
- the cells were re-pelleted by centrifugation at 150 ⁇ g for 5 min, and the pellet was dispersed and mixed with 500 ⁇ l of 1.0% of paraformaldehyde.
- the amount of particles been phagocytized by the peritoneal macrophages was analyzed by flow cytometry.
- mice orally treated with 40 mg/kg/day of PCM significantly elevated the serum level of IgG.
- mice treated with 5 mg/kg/day or higher dose of PCM-K3 showed a significant reduction in the serum level of IgG.
- mice treated with 40 mg/kg/day of PCM 5 mg/kg/day had a significant reduction in IgA secretion in comparison with control group.
- mice treated with the purified components showed a rather different result.
- Oral administration of 10 mg/kg/day or higher dose of PCM-K1 resulted in an increase in IgA secretion by spleen cells in vitro at day 3 and day 5.
- PCM-K3 significantly suppressed the IgA secretion.
- Result from this experiment suggested that oral administration of PCM had an opposite effect between serum level of IgA and the secretion of IgA by spleen cells.
- the purified components such as PCM-K1, K2 or K4 in general did increase the potential of spleen B cells to secret IgA.
- T H 1-type cytokines such as interleukin-2 (IL-2), interferon- ⁇ (IFN- ⁇ ) induces the cellular immune response.
- T H 2-type cytokines such as interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), stimulates the B lymphocyte-mediated humoral immune response.
- IL-2 interleukin-2
- IFN- ⁇ interferon- ⁇
- T H 2-type cytokines such as interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6) stimulates the B lymphocyte-mediated humoral immune response.
- mice were fed with 10 mg and 80 mg/kg/day of PCM, 2.5 mg/kg/day or higher dose of PCM-K1, 2.5 mg/kg/day or higher dose of PCM-K2, 5 mg and 10 mg/kg/day of PCM-K3, and 20 mg/kg/day of PCM-K4, respectively.
- the IFN ⁇ secretion by ConA-stimulated splenic T cells was significantly augmented.
- the spleen cells isolated from the mice treated with 40 mg/kg/day or higher dose had no effect on IL-10 secretion.
- PCM was able to positively regulate T H 1-type cytokine at relatively low dose but it failed to regulate Th2-type cytokine secretion.
- the purified components such as PCM-K1 and -K2 were able to augment both T H 1-type and T H 2-type cytokines secreted.
- CD4 + 8 ⁇ T-cells are predominantly helper T-cells (T H ), and CD4 ⁇ 8 + T-cells are mainly cytotoxic T-lymphocytes (CTL).
- CTL cytotoxic T-lymphocytes
- NK cells play a pivotal role in innate immunity. NK cells non-specifically kill the tumor cells (transformed cells) and viral infected cells. Non-adherent spleen cells isolated from PCM-treated mice were immediately used for NK-mediated cytotoxicity assay. Result indicated that PCM induced an increase in NK-mediated cytotoxicity at 10 mg/kg/day (Table 9). When the dose of PCM was increased, the NK cell activity returned to the basal level. The activation of NK cells is mainly stimulated by Th1-type cytokines. Therefore, this finding correlated well with the augmented effect of PCM on IFN- ⁇ secretion.
- Phagocytic cells are involved in the first line defense against invading pathogens.
- the predominant phagocytic cells in innate immunity are neutrophils and macrophages.
- the peritoneal exudated macrophages were fed with the fluorescent-labeled E. coli , and assayed for the phagocytic activity of elicited macrophages.
- An average 20.88% of macrophages isolated from control group showed phagocytic activity.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/838,545 US20100298283A1 (en) | 2003-05-16 | 2010-07-19 | Pharmaceutical composition for enhancing immunity, and extract of poria |
US14/069,989 US9056067B2 (en) | 2003-05-16 | 2013-11-01 | Pharmaceutical composition for enhancing immunity, and extract of Poria |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW092113393A TWI351961B (en) | 2003-05-16 | 2003-05-16 | Pharmaceutical composition for enhancing immunity, |
TW92113393 | 2003-05-16 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/838,545 Division US20100298283A1 (en) | 2003-05-16 | 2010-07-19 | Pharmaceutical composition for enhancing immunity, and extract of poria |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040229852A1 true US20040229852A1 (en) | 2004-11-18 |
Family
ID=33415060
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/717,559 Abandoned US20040229852A1 (en) | 2003-05-16 | 2003-11-21 | Pharmaceutical composition for enhancing immunity, and extract of Poria |
US12/838,545 Abandoned US20100298283A1 (en) | 2003-05-16 | 2010-07-19 | Pharmaceutical composition for enhancing immunity, and extract of poria |
US14/069,989 Expired - Lifetime US9056067B2 (en) | 2003-05-16 | 2013-11-01 | Pharmaceutical composition for enhancing immunity, and extract of Poria |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/838,545 Abandoned US20100298283A1 (en) | 2003-05-16 | 2010-07-19 | Pharmaceutical composition for enhancing immunity, and extract of poria |
US14/069,989 Expired - Lifetime US9056067B2 (en) | 2003-05-16 | 2013-11-01 | Pharmaceutical composition for enhancing immunity, and extract of Poria |
Country Status (5)
Country | Link |
---|---|
US (3) | US20040229852A1 (ko) |
JP (1) | JP4160532B2 (ko) |
KR (1) | KR100613625B1 (ko) |
CA (1) | CA2467265C (ko) |
TW (1) | TWI351961B (ko) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090247496A1 (en) * | 2008-03-31 | 2009-10-01 | Sinphar Pharmaceutical Co., Ltd. | Pharmaceutical composition and extract of poria for enhancing uptake of nutrients |
WO2009124420A1 (zh) | 2008-04-11 | 2009-10-15 | 杏辉天力(杭州)药业有限公司 | 促进营养素被吸收的医药组合物及茯苓萃取物 |
US20090318399A1 (en) * | 2008-06-20 | 2009-12-24 | Sinphar Pharmaceutical Co., Ltd. | Pharmaceutical composition and extract of poria for treating a disease induced from immune disorder |
EP2246047A1 (en) | 2009-05-02 | 2010-11-03 | Sinphar Tian-li Pharmaceutical Co., Ltd. (Hangzhou) | Use of Lanostane derivatives in treating Cachexia |
US20110053899A1 (en) * | 2009-08-28 | 2011-03-03 | Sinphar Tian-Li Pharmaceutical Co., Ltd (Hangzhou) | Use of lanostane and poria extract in treating diabetes |
KR101544804B1 (ko) * | 2008-06-24 | 2015-08-17 | 신파 티엔리 파머슈티컬 컴퍼니 리미티드 (항저우) | 면역장애로부터 유발된 질환을 치료하기 위한 약학적 조성물 및 복령 추출물 |
US9910051B2 (en) | 2006-10-27 | 2018-03-06 | Life Technologies Corporation | Fluorogenic pH sensitive dyes and their method of use |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014088200A1 (ko) * | 2012-12-06 | 2014-06-12 | 한국식품연구원 | 복령피 추출물, 백미 추출물 또는 남성 추출물을 유효성분으로 포함하는 면역 질환의 예방, 개선 또는 치료용 조성물 |
JP5883901B2 (ja) * | 2014-06-17 | 2016-03-15 | 杏輝天力(杭州)藥業有限公司 | 免疫障害により誘起される疾患の治療のための医薬組成物およびポリア抽出物 |
CN114128658B (zh) * | 2021-11-25 | 2023-03-24 | 中国水产科学研究院黑龙江水产研究所 | 一种用于人工鱼巢的改性椰丝材料的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020068098A1 (en) * | 2000-08-01 | 2002-06-06 | Ashni Naturaceuticals, Inc. | Combinations of diterpene triepoxide lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08119864A (ja) * | 1994-09-02 | 1996-05-14 | Kotarou Kanpo Seiyaku Kk | 鎮吐薬 |
JP2005089328A (ja) * | 2003-09-12 | 2005-04-07 | Univ Nihon | Dna合成酵素及びdnaトポイソメラーゼ阻害性組成物 |
TWI367099B (en) * | 2008-06-20 | 2012-07-01 | Sinphar Pharmaceutial Co Ltd | Pharmaceutical composition and extract of poria for treating a disease induced from immune disorder |
CN101874807B (zh) * | 2009-05-02 | 2013-04-10 | 杏辉天力(杭州)药业有限公司 | 以羊毛固醇及茯苓萃取物治疗恶病质的用途 |
-
2003
- 2003-05-16 TW TW092113393A patent/TWI351961B/zh not_active IP Right Cessation
- 2003-11-21 US US10/717,559 patent/US20040229852A1/en not_active Abandoned
-
2004
- 2004-05-12 KR KR1020040033435A patent/KR100613625B1/ko active IP Right Grant
- 2004-05-13 CA CA002467265A patent/CA2467265C/en not_active Expired - Lifetime
- 2004-05-14 JP JP2004145225A patent/JP4160532B2/ja not_active Expired - Fee Related
-
2010
- 2010-07-19 US US12/838,545 patent/US20100298283A1/en not_active Abandoned
-
2013
- 2013-11-01 US US14/069,989 patent/US9056067B2/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020068098A1 (en) * | 2000-08-01 | 2002-06-06 | Ashni Naturaceuticals, Inc. | Combinations of diterpene triepoxide lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2 |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11867698B2 (en) | 2006-10-27 | 2024-01-09 | Life Technologies Corporation | Fluorogenic pH sensitive dyes and their method of use |
US10845373B2 (en) | 2006-10-27 | 2020-11-24 | Life Technologies Corporation | Fluorogenic pH sensitive dyes and their method of use |
US9939454B2 (en) | 2006-10-27 | 2018-04-10 | Life Technologies Corporation | Fluorogenic pH sensitive dyes and their method of use |
US9910051B2 (en) | 2006-10-27 | 2018-03-06 | Life Technologies Corporation | Fluorogenic pH sensitive dyes and their method of use |
US20090247496A1 (en) * | 2008-03-31 | 2009-10-01 | Sinphar Pharmaceutical Co., Ltd. | Pharmaceutical composition and extract of poria for enhancing uptake of nutrients |
US9757392B2 (en) * | 2008-03-31 | 2017-09-12 | Sinphar Pharmaceutical Co., Ltd. | Pharmaceutical composition and extract of Poria for enhancing uptake of nutrients |
WO2009124420A1 (zh) | 2008-04-11 | 2009-10-15 | 杏辉天力(杭州)药业有限公司 | 促进营养素被吸收的医药组合物及茯苓萃取物 |
KR101488332B1 (ko) * | 2008-04-11 | 2015-02-02 | 신파 티엔리 파머슈티컬 컴퍼니 리미티드 (항저우) | 영양분의 흡수를 증가시키는데 효과적인 약학적 조성물 및 복령 추출물 |
US20090318399A1 (en) * | 2008-06-20 | 2009-12-24 | Sinphar Pharmaceutical Co., Ltd. | Pharmaceutical composition and extract of poria for treating a disease induced from immune disorder |
KR101544804B1 (ko) * | 2008-06-24 | 2015-08-17 | 신파 티엔리 파머슈티컬 컴퍼니 리미티드 (항저우) | 면역장애로부터 유발된 질환을 치료하기 위한 약학적 조성물 및 복령 추출물 |
US20100279992A1 (en) * | 2009-05-02 | 2010-11-04 | Sinphar Tian-Li Pharmaceutical Co., Ltd (Hangzhou) | Use of lanostane and poria extract in treating cachexia |
US8658629B2 (en) | 2009-05-02 | 2014-02-25 | Sinphar Tian-Li Pharmaceutical Co., Ltd. | Use of lanostane and Poria extract in treating cachexia |
KR101140753B1 (ko) * | 2009-05-02 | 2012-05-03 | 신파 티엔리 파머슈티컬 컴퍼니 리미티드 (항저우) | 악액질 치료에서 라노스테인 및 복령 추출물의 용도 |
EP2246047A1 (en) | 2009-05-02 | 2010-11-03 | Sinphar Tian-li Pharmaceutical Co., Ltd. (Hangzhou) | Use of Lanostane derivatives in treating Cachexia |
US9084798B2 (en) | 2009-08-28 | 2015-07-21 | Sinphar Tian-Li Pharmaceutical Co., Ltd (Hangzhou) | Use of lanostane and Poria extract in treating diabetes |
EP2298320A1 (en) | 2009-08-28 | 2011-03-23 | Sinphar Tian-li Pharmaceutical Co., Ltd. (Hangzhou) | Use of lanostane and poria extract in treating diabetes |
US20110053899A1 (en) * | 2009-08-28 | 2011-03-03 | Sinphar Tian-Li Pharmaceutical Co., Ltd (Hangzhou) | Use of lanostane and poria extract in treating diabetes |
Also Published As
Publication number | Publication date |
---|---|
US20140065174A1 (en) | 2014-03-06 |
TW200425900A (en) | 2004-12-01 |
CA2467265A1 (en) | 2004-11-16 |
KR20040099134A (ko) | 2004-11-26 |
TWI351961B (en) | 2011-11-11 |
JP2004339220A (ja) | 2004-12-02 |
US9056067B2 (en) | 2015-06-16 |
KR100613625B1 (ko) | 2006-08-17 |
CA2467265C (en) | 2008-03-25 |
JP4160532B2 (ja) | 2008-10-01 |
US20100298283A1 (en) | 2010-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9056067B2 (en) | Pharmaceutical composition for enhancing immunity, and extract of Poria | |
Bouic et al. | Beta-sitosterol and beta-sitosterol glucoside stimulate human peripheral blood lymphocyte proliferation: implications for their use as an immunomodulatory vitamin combination | |
KR100767701B1 (ko) | 모노아세틸디아실글리세롤류 화합물을 유효성분으로 함유하는 면역조절제 및 항암제 | |
Yi et al. | Immunomodulatory effects of betulinic acid from the bark of white birch on mice | |
EP2246047B1 (en) | Use of lanostane derivatives in treating cachexia | |
RU2687498C2 (ru) | Экстракт водорослей для использования в качестве иммуномодулирующего агента | |
TWI394572B (zh) | Application of Cynanchum aurantii Cyclohexenone Compounds in the Preparation of Drugs for the Treatment of Autoimmune Diseases | |
Shin et al. | Immunostimulatory effects of cordycepin‐enriched WIB‐801CE from Cordyceps militaris in splenocytes and cyclophosphamide‐induced immunosuppressed mice | |
Takano et al. | The liquid culture filtrates of Paecilomyces tenuipes (Peck) Samson (= Isaria japonica Yasuda) and Paecilomyces cicadae (Miquel) Samson (= Isaria sinclairii (Berk.) Llond) regulate Th1 and Th2 cytokine response in murine Peyer's patch cells in vitro and ex vivo | |
KR101544804B1 (ko) | 면역장애로부터 유발된 질환을 치료하기 위한 약학적 조성물 및 복령 추출물 | |
JPH11501634A (ja) | 免疫系異常治療用の胆汁からの免疫調節組成物 | |
JP2007063244A (ja) | トリテルペン化合物、その製造方法及びそれを有効成分として含有する発癌プロモーション抑制組成物 | |
CN111202737B (zh) | 雷公藤红素酰胺衍生物在制备治疗自身性免疫疾病药物的应用 | |
EP1535619B1 (en) | Poria extract devoid of secolanostane derivatives comprising lanostane derivatives for immunity enhancement | |
CN110016007B (zh) | 环状二苯基庚烷类化合物、其制备方法、其应用、药物及膳食补充剂 | |
KR20120069221A (ko) | 봉독조성물 | |
JP4460286B2 (ja) | 気管支呼吸困難の治療及び療法のための草本組成物 | |
Ye et al. | Stemucronatoside K, a novel C21 steroidal glycoside from Stephanotis mucronata, inhibited the cellular and humoral immune response in mice | |
Yamaguchi et al. | Capsicum extract and its constituents modulated the production of immunoglobulins in Peyer’s patch cells ex vivo | |
CN107056878B (zh) | 一个d-吡喃环孕甾烷糖苷化合物及其应用 | |
CN104958305A (zh) | 治疗免疫失调所引起的疾病的医药组合物及茯苓萃取物 | |
JP2004059558A (ja) | きのこ類から生理活性物質の採取法及びその生理活性物質の製剤及びその使用法 | |
KR20050110379A (ko) | 면역기능 향상을 위한 약제학적 조성물 및 복령 추출물 | |
CN109432116A (zh) | 黄芪皂苷ⅲ在制备肿瘤免疫治疗药物中的用途 | |
US20070258989A1 (en) | Immunomodulatory pharmaceutical composition and a process for preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SINPHAR PHARMACEUTICAL CO., LTD., TAIWAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIN, HANG-CHING;TSENG, JERMING;DING, HSDIOU-YU;AND OTHERS;REEL/FRAME:014729/0157;SIGNING DATES FROM 20031025 TO 20031110 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |